Kissei Pharmaceutical Co., Ltd. (Kissei) develops, manufactures, and sells pharmaceutical products. The company's portfolio includes medicines for urological, metabolic, endocrinological, obstetrics and gynecological, nephrological, ophthalmic, and pulmonary system diseases and disorders. It is also involved in the purchasing and sale of related materials, the manufacture, production, and sale of noodle products, system integration and system resource services, general construction, factory and building management, information gathering and development support, and other services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kissie is committed to being an R&D-oriented pharmaceutical company, focusing on the research and development of innovative pharmaceutical products. The company has a strong emphasis on drug discovery in areas such as urology, renal diseases, dialysis, and rare and intractable diseases. The company leverages open innovation and digital technologies, including AI, to enhance the speed and quality of its drug discovery research. It is actively investing in R&D, IT, and facilities to support its growth strategy and aims to bring a steady stream of new drugs to market. CG0070, a treatment for non-muscle invasive bladder cancer, is progressing through an international Phase III clinical trial led by CG Oncology (US), with trials also underway in Japan. Another major project, Linzagolix (KLH-2109), which addresses uterine fibroids and endometriosis, is in Phase III clinical trials in Japan for uterine fibroids. Kissei is strengthening its small molecule drug discovery system, advancing drug discovery themes to clinical stages efficiently, and expanding its product portfolio through strategic licensing. In the information services sector, it is developing systems and software to address social issues in healthcare and nursing, leveraging next-generation technologies. The company operates its R&D activities through four laboratories, which include Central Research Laboratories, Safety Research Laboratories, Joetsu Chemical Laboratories and Pharmaceutical Laboratories. In FY2025, the company spent JPY12,889 million on its R&D activities, which as a percentage of its revenue stood at 14.5% and increased 36% YoY.